Genomic Profiling of Hormone-Naïve Lymph Node Metastases in Patients with Prostate Cancer

Department of Urology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA.
Neoplasia (New York, N.Y.) (Impact Factor: 5.4). 01/2007; 8(12):1083-9. DOI: 10.1593/neo.06421
Source: PubMed

ABSTRACT The progression of organ-confined prostate cancer to metastatic cancer is inevitably fatal. Consequently, identification of structural changes in the genome and associated transcriptional responses that drive this progression is critical to understanding the disease process and the development of biomarkers and therapeutic targets. In this study, whole genome copy number changes in genomes of hormone-naïve lymph node metastases were profiled using array comparative genomic hybridization, and matched primaries were included for a subset. Matched primaries and lymph node metastases showed very similar copy number profiles that are distinct from primary tumors that fail to metastasize.

Download full-text


Available from: Giancarlo Albo, Jan 30, 2014
  • Source
    • "Using aCGH, we previously found a significant concordance between the copy number changes in primary prostate tumors and unmatched metastatic tumors [31]. Also, copy number changes of matched primary prostate tumor and hormone naïve lymph node metastasis are almost identical, suggesting that this method could be used for detecting genomic biomarkers with associated metastatic phenotypes [32]. Based on these observations, we hypothesize that a subset of copy number aberrations representative of a primary tumor and its metastatic lesions can be identified in CTCs, and thereby potentially extending the clinical utility of such a biomarker. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating tumor cells (CTCs) hold promise for studying advanced prostate cancer. A functional collagen adhesion matrix (CAM) assay was used to enrich CTCs from prostate cancer patients' blood. CAM ingestion and epithelial immuno-staining identified CTCs, which were genotyped using oligonucleotide array comparative genomic hybridization. The highest CTC counts were observed in men with metastatic castration resistant prostate cancer (CRPC) compared to castration sensitive prostate cancer. Copy number profiles for CRPC CTCs were similar to paired solid tumor DNA, and distinct from corresponding DNA from the residual CAM-depleted blood. CAM CTC enrichment may allow cellular and genetic analyses in prostate cancer.
    Cancer letters 02/2009; 277(2):164-73. DOI:10.1016/j.canlet.2008.12.007 · 5.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The current focus on biomarker discovery is a result of an improved understanding of the biological basis for carcinogenesis and advances in technology. Biomarkers can aid in diagnosis, prognosis, treatment selection, and drug development. There is an urgent need for high-resolution tools that perform well using archived tissue for biomarker discovery and tools that can translate into the clinic. Oligonucleotide array comparative genomic hybridization (oCGH) was compared to BAC-based aCGH using unamplified total genomic DNA from formalin fixed paraffin-embedded (FFPE) prostate tissue. The copy number aberrations detected with the BAC and oligonucleotide arrays were highly correlated in cases where the arrays contained probes in similar genomic locations. The oligonucleotide array platform provided more precise mapping due to the higher density of oligonucleotide probes. These results demonstrate the utility of high-resolution oligonucleotide arrays designed to use genomic DNA for CGH measurements using archived tissue samples for discovery and clinic based assays.
    The Prostate 09/2007; 67(13):1447-55. DOI:10.1002/pros.20632 · 3.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This issue marks the 10th year anniversary of Neoplasia where we have seen exciting growth on the impact that Neoplasia has had on cancer research worldwide. Neoplasia was founded in 1999 at which time manuscripts were accepted through e-mail. In 2000, Neoplasia became the first journal to offer web-based online manuscript submission and peer-review using a custom-designed application JournalSoft. Now, the use of web-based manuscript processing has become an industry standard as it provides authors with a rapid and useful dialog exchange for improving the quality of the science and the overall speed of the review process. Moreover, during the past 10 years, the Internet has experienced a massive growth of a complex global grid of now over an estimated 1.2 billion Internet users which have resulted in a major shift in the medium of scientific communication for scholarly publishing. Neoplasia continues to evolve with the technology and has implemented a rapid time-to-publication schedule to continue dissemination of published cancer research findings quickly to the scientific community.
    Neoplasia (New York, N.Y.) 12/2007; 9(12). DOI:10.1593/neo.07968 · 5.40 Impact Factor
Show more